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Abstract
Blood lipids and high sensitivity C-reactive protein (hsCRP) are altered by hormone therapy. The
goal of the current study was to determine whether lipids and hsCRP have predictive value for
hormone therapy benefit or risk for coronary heart disease (CHD) events in postmenopausal
women without previous cardiovascular disease. A nested case-control study was performed in the
Women’s Health Initiative hormone trials. Baseline lipids and hsCRP were obtained from 271
incident CHD cases and 707 controls. In a combined trial analysis, a favorable lipid status at
baseline tended to predict better CHD outcomes when taking conjugated equine estrogen (CEE)
with or without medroxyprogesterone acetate (MPA). Women with a low density lipoprotein
(LDL)/high density lipoprotein (HDL) ratio <2.5 had no increase in risk of CHD when taking CEE
with or without MPA (OR 0.60, 95%CI=0.34–1.06), whereas women with an LDL/HDL ratio
≥2.5 had an increased risk of CHD (OR 1.73, 95%CI=1.18–2.53) (p-value for interaction = 0.02).
Low hsCRP levels added marginally to the value of LDL/HDL<2.5 when predicting CHD benefit
on hormone therapy. In conclusion, postmenopausal women with undesirable lipid levels had
excess CHD risk when using CEE with or without MPA; however, women with favorable lipid
levels, especially an LDL/HDL ratio < 2.5, did not have an elevated risk of CHD with CEE with
or without MPA, irrespective of hsCRP levels.
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It remains uncertain whether routinely available CHD biomarkers, such as lipids and hsCRP,
may help to identify women at higher or lower risk of incident coronary events mediated by
menopausal hormone therapy. The WHI conducted 2 clinical trials, assessing the effect of
CEE alone in women without a uterus or CEE+MPA in postmenopausal women who had
not undergone hysterectomy. Neither Women’s Health Initiative trial showed an overall
protective effect of hormone therapy for coronary events,1, 2 in contrast to results of earlier
observational studies.3, 4 The reasons for this discrepancy are not yet determined but may be
related to differences in baseline CHD risks of the study populations and the distributions of
risk factors such as lipids and hsCRP. Because clinical trials have demonstrated a small
overall increase in the absolute risk of short term hormone therapy use for CHD events in
postmenopausal women, we asked whether commonly utilized biomarkers (lipids and
hsCRP) could be useful for predicting hormone therapy-mediated CHD risk. We performed
a nested case-control study of biomarkers obtained at baseline and 1 year follow-up in
women from both WHI hormone trials. The goal of this study was to determine whether
baseline lipids and hsCRP have predictive value for hormone therapy benefit or risk for
CHD events.
Methods
Eligibility criteria and recruitment methods have been published for both Women’s Health
Initiative clinical trials.5–7 From September 1993 to October 1998 generally healthy
postmenopausal women aged 50 to 79 years were enrolled in 40 US clinical centers. Study
participants provided informed consent via forms approved by each center’s institutional
review board. Eligible women with an intact uterus (n=16,608) were randomly assigned to
receive 0.625 mg/d of CEE plus 2.5 mg/d MPA or a matching placebo. Eligible women who
had undergone hysterectomy (n=10,739) were randomly assigned to receive 0.625 mg/d of
CEE or a matching placebo.
A case-control biomarker study was nested within the 2 hormone clinical trials (note that
lipid and hsCRP levels were performed only in a subset of participants in these trials). The
current study represents a nested case-control analysis of biomarkers in 271 incident CHD
cases and 707 controls. Reasoning that future hormone therapy use is likely to be
discouraged for women with pre-existing cardiovascular disease, we included only those
women without baseline cardiovascular disease. Outcome definitions and methods for
ascertaining, documenting, and classifying outcomes have been published.8 Women with a
history of myocardial infarction, angina, coronary revascularization or stroke prior to study
entry were excluded. Cases were defined as all incident acute myocardial infarction
requiring overnight hospitalization and/or CHD death in either clinical trial that occurred in
the first 4 years of follow-up. Incident myocardial infarction is defined as a clinical
myocardial infarction presenting with chest discomfort, typical ECG changes, and elevation
of cardiac-specific enzymes,, and does not include silent or possible silent myocardial
infarctions. Case status was determined by central adjudication based on review of medical
records. Controls are defined as women who did not experience a cardiovascular disease
event during the entire duration of follow-up in the Women’s Health Initiative clinical trial.
The case/control selection process was done matching age at screening, randomization date
and hysterectomy status.
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Baseline and year 1 blood samples were obtained in a fasting state. The specimens were
centrifuged, serum and plasma was frozen at −70°C, and shipped on dry ice to a central
processing facility. Subjects who became cases within the first year of follow-up did not
have their year 1 biomarkers measured. Lipids were measured in ethylenediaminetetraacetic
acid -anticoagulated plasma at PPD Global Central Labs (Highland Heights, KY), formerly
Medical Research Laboratories International, on a Hitachi 747 General Chemistry Analyzer.
Triglycerides were measured by a chromogenic reaction after hydrolysis and oxidation.
Total cholesterol was measured enzymatically utilizing cholesterol esterase and cholesterol
oxidase. HDL cholesterol was measured after removal of chylomicrons, very low density
lipoproteins and LDL from the plasma. LDL-cholesterol was calculated using the
Friedewald formula (total cholesterol-HDL cholesterol-triglyceride/5). Lipoprotein(a) levels
were measured by an enzyme immunoassay. hsCRP was measured in serum using the Dade
Behring N Latex High Sensitivity hsCRP™ mono assay on the Behring Nephelometer II
according to manufacturer’s recommendations.
Means and frequencies are presented for demographic data. CHD cases and controls were
compared using a 2-sample t-test (continuous variables) or a Chi-Square test (categorical
variables). To account for the skewed distribution of the biomarker data, geometric means
and standard deviations were calculated for the individual markers. For the ratio variables,
which are normally distributed, standard means and deviations were calculated. Testing for
descriptive tables was based on a t-test using the logged distribution for the individual
biomarkers. All modeling was logistic with both odds ratios and p-values presented in the
resulting tables. Interaction models were also fitted using logistic regression including terms
for the main effects of the biomarker level of interest (e.g., high LDL/HDL ratio), treatment
assignment, and their interaction. The resulting p-value for the interaction term is presented
in the tables. All models were adjusted for age, year of randomization, history of
hypertension (defined as self-report of pill usage or measured systolic blood pressure ≥ 140
or diastolic blood pressure ≥ 90), body mass index, current smoking, self report of
cholesterol-lowering medication use, and self-report of treated diabetes. Additional logistic
models were run to examine the linear trend of combinations of LDL/HDL ratio and hsCRP
on CHD, assigning values to each LDL/HDL ratio and hsCRP combination. All analyses
were conducted using SAS 9.1 (SAS Institute, Cary, NC).
Results
Table 1 shows the baseline characteristics of the study subjects separated by clinical trial
and for the trials combined. Increased BMI, current smoking, treated diabetes, and self-
reported hypertension predicted case status in the combined trials. Mean baseline values for
all biomarkers tended toward a “less desirable” direction in the women in the CEE trial
compared to the women in the CEE+MPA trial, but only the mean triglyceride,
lipoprotein(a) and hsCRP levels were significantly different between the 2 trials (Table 2).
All biomarkers shown in Table 2 except lipoprotein(a) were associated with CHD risk, but
the strength of the association varied by treatment group and clinical trial (see online
Supplemental Tables).
We examined whether there were associations between the hormone therapy effect on
incident CHD and the level of each lipid biomarker or hsCRP (Table 3). Subjects were
grouped by desirable or undesirable HDL-cholesterol and triglyceride levels using ATP III
recommended cut-offs,9 and the median biomarker level of healthy controls for LDL-
cholesterol, non-HDL-cholesterol, Lp(a) and the total cholesterol (TC)/HDL and
triglyceride/HDL ratios. The cut-off for the LDL/HDL ratio was based on desirable values
of 100 and 40, respectively. Women with higher levels of LDL-cholesterol, and the total
cholesterol/HDL and LDL/HDL ratios had elevated risks of CHD when using CEE+MPA,
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while women with lower levels of these biomarkers did not. A similar trend was observed
for the LDL/HDL ratio in the CEE trial. When the trials were combined, there was a
significant interaction between HT and the biomarker for LDL-cholesterol, non-HDL-
cholesterol, the total cholesterol/HDL ratio and the LDL/HDL ratio. hsCRP showed a
significant interaction with CEE alone but not CEE+MPA.
We utilized the baseline LDL/HDL ratio biomarker in combination with hsCRP in a
combined trial analysis to evaluate CHD risk due to hormone therapy (Table 4). Women
who had low LDL/HDL ratios at baseline did not experience an increased risk of CHD
events on hormone therapy, regardless of hsCRP level, whereas women with elevated LDL/
HDL ratios had increased risks of hormone therapy-mediated CHD, regardless of hsCRP
levels.
Discussion
This study was designed to assess whether routinely available CHD biomarkers were useful
for predicting the risk of incident myocardial infarction and/or CHD death in
postmenopausal women without cardiovascular disease who had initiated CEE with or
without MPA. The major findings were that several baseline lipid measurements, but
especially the LDL/HDL ratio, interact with CEE with or without MPA to modify the risk
for CHD. Specifically, women with baseline LDL/HDL ratios above 2.5 were at an
increased CHD risk due to CEE with or without MPA, whereas there was no increased CHD
risk due to CEE with or without MPA when the baseline LDL/HDL ratio was less than 2.5.
We also found evidence that hsCRP added little or no additional predictive value beyond the
LDL/HDL biomarker for predicting CHD risk for women using hormone therapy.
Women with baseline HDL-cholesterol <50, or with LDL-cholesterol, total cholesterol/HDL
ratio and LDL/HDL ratio above the median control value, were at increased CHD risk when
assigned to CEE+MPA, and similar trends were observed with unopposed CEE.
Importantly, we found no clear evidence that either form of hormone therapy posed a risk
for CHD events for women with baseline HDL-cholesterol ≥50, or with LDL-cholesterol,
total cholesterol/HDL ratio and LDL/HDL ratio below the median control value. When
analyzed using median control values for HDL and trigyceride (53 and 135, respectively)
instead of the ATP III recommended cutoffs (50 and 150, respectively), the results were
essentially the same.
Our analysis has provided a side-by-side comparison of the effect of biomarkers in the 2
Women’s Health Initiative hormone trials. The odds ratios for the treatment effect by
baseline LDL-cholesterol, HDL-cholesterol, non-HDL-cholesterol, the total cholesterol/
HDL ratio and the LDL/HDL ratio were similar for both the CEE+MPA and CEE clinical
trials. These similar responses provide support for combining the 2 trials in the analyses of
these latter biomarkers. In the combined Women’s Health Initiative hormone trial analysis,
with an LDL/HDL ratio <2.5 the OR for hormone therapy effect of 0.6 (95%CI=0.34–1.06),
underscoring the potential CHD safety of hormone therapy in women with a desirable,
“healthy” lipid profile. These results were not materially affected when women using
cholesterol-lowering drugs were excluded from the analyses (data not shown).
How might lipids and hormone therapy interact mechanistically to affect the risk for CHD?
There is strong animal data that estrogen is cardioprotective in hyperlipidemic animals when
administered at the time of menopause and/or prior to the development of atherosclerosis 10.
Our study specifically excluded women with prior CHD, yet we still observed an interaction
between hormone therapy and baseline cholesterol levels for CHD risk even after adjusting
for age. Recently, the cholesterol metabolite, 27-hydroxycholesterol, has been shown to
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compete with estrogen for binding to vascular estrogen receptors, blocking the beneficial
effects of estrogen (nitric oxide production and endothelial cell migration) on murine
vascular cells 11. This study by Umetani et al. suggests an attractive and testable hypothesis:
that postmenopausal women with a poor lipid profile have elevated levels of 27-
hydroxycholesterol, which disables a potential vascular benefit of estrogen. Conversely, the
women in the Women’s Health Initiative clinical trials with favorable lipids might
experience no harm or even benefit from estrogen therapy if they have low levels of 27-
hydroxycholesterol.
Since elevated plasma triglyceride levels are thought to be a risk factor for CHD in women12
and hormone therapy increases triglyceride levels, it was important to consider the
relationship between triglyceride and hormone therapy for CHD events. Our analyses
showed high baseline levels of triglyceride were associated with CHD cases in only the CEE
+MPA trial, but not the CEE trial (online supplemental data), but we observed no interaction
between baseline triglyceride and CEE with or without MPA for CHD events. We also
assessed whether the year 1 triglyceride levels or the change from baseline to year 1
triglyceride level were related to developing CHD events, but found no relationship.
The difference in study design between the current biomarker study and the overall
Women’s Health Initiative hormone trials should be noted. Only women developing CHD
events within the first 4 years comprised cases for this biomarker study, and later events
were not analyzed. Any conclusions from the current report only pertain to this time frame.
Although this study is comparable in size to other large biomarker studies, the planned
subgroup analysis nevertheless had relatively small numbers of cases, and we did not have a
sufficient sample size to stratify by age.
Despite increasing information and understanding of the clinical benefits and risks of
hormone therapy, practitioners are still challenged in making management choices for
individual postmenopausal women. The Framingham risk prediction model specifically did
not include estrogen replacement therapy use in formulating CHD risk assessment,13 and no
convincing data has previously defined whether hormone therapy modifies the CHD risk
associated with increased lipid levels (or other biomarkers). This report has just considered
the risks and benefits associated with CHD outcomes, and the decision to use
postmenopausal hormones must consider the totality of health risks and benefits, including
stroke, thrombosis and gall bladder disease. Women considering the use of postmenopausal
hormone therapy should determine their overall cardiac risk and specifically their lipid
profile. The absolute excess CHD risk is low or absent in younger women who take CEE
with or without MPA.14 Our study provides support that CEE with or without MPA may not
increase the short term CHD risk among women with a favorable lipid profile.
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